Oncopeptides AB (publ) (STO: ONCO)
Sweden
· Delayed Price · Currency is SEK 2.175
-0.035 (-1.58%)
Sep 2, 2024, 11:19 AM CET
Oncopeptides AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 119.15 | 138.15 | 190.53 | 379.45 | 116.39 | 126.98 | Upgrade
|
| Cash & Short-Term Investments | 119.15 | 138.15 | 190.53 | 379.45 | 116.39 | 126.98 | Upgrade
|
| Cash Growth | -24.00% | -27.49% | -49.79% | 226.01% | -8.34% | -53.47% | Upgrade
|
| Accounts Receivable | - | - | 0.56 | 1.63 | 13.38 | - | Upgrade
|
| Other Receivables | 1.84 | 2.43 | 4.42 | 5.57 | 5 | 4.16 | Upgrade
|
| Receivables | 1.84 | 2.43 | 4.98 | 7.2 | 18.38 | 4.16 | Upgrade
|
| Prepaid Expenses | 2.88 | 0.01 | 0.39 | 0.51 | 0.45 | 0.75 | Upgrade
|
| Other Current Assets | -0 | - | 13.85 | 7.46 | 4.62 | 5.12 | Upgrade
|
| Total Current Assets | 123.87 | 140.59 | 209.75 | 394.61 | 139.84 | 137.02 | Upgrade
|
| Property, Plant & Equipment | 0 | 0 | 0.09 | 1.75 | 3.26 | 4.43 | Upgrade
|
| Long-Term Investments | - | - | 0.05 | - | - | - | Upgrade
|
| Other Intangible Assets | - | - | - | - | - | 0.09 | Upgrade
|
| Other Long-Term Assets | - | - | - | 5.01 | 5.03 | 4.92 | Upgrade
|
| Total Assets | 123.87 | 140.6 | 209.89 | 401.36 | 148.13 | 146.47 | Upgrade
|
| Accounts Payable | 2.26 | 1.99 | 7.87 | 17.74 | 20.89 | 10.25 | Upgrade
|
| Accrued Expenses | 18.45 | 15.03 | 40.88 | 54.51 | 53.25 | 21.12 | Upgrade
|
| Current Portion of Leases | - | - | - | 1.54 | 1.68 | 1.43 | Upgrade
|
| Other Current Liabilities | 0.62 | 1.23 | 1.79 | 9.23 | 4.31 | 6.01 | Upgrade
|
| Total Current Liabilities | 21.33 | 18.25 | 50.54 | 83.02 | 80.12 | 38.8 | Upgrade
|
| Long-Term Leases | - | - | - | 0.11 | 1.44 | 2.76 | Upgrade
|
| Other Long-Term Liabilities | 0.63 | 0.91 | 0.85 | - | - | - | Upgrade
|
| Total Liabilities | 21.96 | 19.16 | 51.39 | 83.13 | 81.56 | 41.56 | Upgrade
|
| Common Stock | 4.95 | 4.95 | 4.95 | 4.95 | 2.55 | 0.98 | Upgrade
|
| Additional Paid-In Capital | 1,218 | 1,218 | 1,218 | 1,218 | 768.08 | 619 | Upgrade
|
| Retained Earnings | -1,121 | -1,102 | -1,065 | -904.32 | -704.07 | -515.08 | Upgrade
|
| Comprensive Income & Other | 0 | 0 | - | 0 | 0 | - | Upgrade
|
| Shareholders' Equity | 101.91 | 121.43 | 158.5 | 318.23 | 66.57 | 104.91 | Upgrade
|
| Total Liabilities & Equity | 123.87 | 140.6 | 209.89 | 401.36 | 148.13 | 146.47 | Upgrade
|
| Total Debt | - | - | - | 1.65 | 3.12 | 4.19 | Upgrade
|
| Net Cash (Debt) | 119.15 | 138.15 | 190.53 | 377.8 | 113.28 | 122.8 | Upgrade
|
| Net Cash Growth | -24.00% | -27.49% | -49.57% | 233.52% | -7.75% | -55.00% | Upgrade
|
| Net Cash Per Share | 0.73 | 0.86 | 1.18 | 3.01 | 1.84 | 3.83 | Upgrade
|
| Filing Date Shares Outstanding | 161.52 | 161.52 | 161.52 | 161.52 | 83.37 | 32.05 | Upgrade
|
| Total Common Shares Outstanding | 161.52 | 161.52 | 161.52 | 161.52 | 83.37 | 32.05 | Upgrade
|
| Working Capital | 102.54 | 122.34 | 159.21 | 311.59 | 59.72 | 98.22 | Upgrade
|
| Book Value Per Share | 0.63 | 0.75 | 0.98 | 1.97 | 0.80 | 3.27 | Upgrade
|
| Tangible Book Value | 101.91 | 121.43 | 158.5 | 318.23 | 66.57 | 104.81 | Upgrade
|
| Tangible Book Value Per Share | 0.63 | 0.75 | 0.98 | 1.97 | 0.80 | 3.27 | Upgrade
|
| Machinery | - | 0.07 | 0.54 | 0.54 | 0.54 | 0.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.